Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB lowered its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 24.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 114,000 shares of the company’s stock after selling 36,000 shares during the quarter. Rhenman & Partners Asset Management AB owned about 0.39% of Dianthus Therapeutics worth $2,485,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. R Squared Ltd purchased a new position in Dianthus Therapeutics during the fourth quarter worth approximately $26,000. KLP Kapitalforvaltning AS acquired a new stake in Dianthus Therapeutics during the fourth quarter worth about $33,000. KBC Group NV purchased a new position in shares of Dianthus Therapeutics in the 4th quarter worth about $35,000. AlphaQuest LLC lifted its stake in shares of Dianthus Therapeutics by 273.1% in the 4th quarter. AlphaQuest LLC now owns 4,197 shares of the company’s stock valued at $91,000 after purchasing an additional 3,072 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new stake in shares of Dianthus Therapeutics during the 4th quarter worth about $201,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Trading Down 5.0 %

Dianthus Therapeutics stock opened at $16.12 on Friday. Dianthus Therapeutics, Inc. has a 52 week low of $14.78 and a 52 week high of $32.27. The stock has a market cap of $517.86 million, a P/E ratio of -6.45 and a beta of 1.62. The stock has a 50 day moving average of $21.48 and a 200-day moving average of $23.92.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.04. The company had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. As a group, equities analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Analysts Set New Price Targets

DNTH has been the topic of several research reports. TD Cowen assumed coverage on shares of Dianthus Therapeutics in a research report on Friday, December 20th. They set a “buy” rating on the stock. Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Wedbush reiterated an “outperform” rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Guggenheim restated a “buy” rating and set a $84.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Dianthus Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $54.33.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.